383 related articles for article (PubMed ID: 25608973)
1. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
[TBL] [Abstract][Full Text] [Related]
2. Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
Apolinário AC; Sindeaux R; de Souza Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; de Paula AP; de Paula LM; de Melo NS; Leite AF
Dentomaxillofac Radiol; 2016; 45(4):20150400. PubMed ID: 26954289
[TBL] [Abstract][Full Text] [Related]
3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
8. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
9. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
10. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Sousa T; Bompadre V; White KK
J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
[TBL] [Abstract][Full Text] [Related]
12. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
13. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Zeitlin L; Rauch F; Plotkin H; Glorieux FH
Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
15. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
17. Therapy with pamidronate in children with osteogenesis imperfecta.
Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
Rauch F; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
Lin HY; Lin SP; Chuang CK; Chen MR; Chang CY
Pediatr Neonatol; 2008 Oct; 49(5):161-5. PubMed ID: 19133566
[TBL] [Abstract][Full Text] [Related]
20. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
